While SGLT-2 inhibitors reduce the risk of cardiovascular diseases, other antidiabetic medications such as glucagon-like-1 (GLP-1) receptor agonists, and the thiazolidinediones such as pioglitazone, have also been shown to exert cardioprotective effects, albeit via very different mechanisms from SGLT-2 inhibitors. Here, SLC5A2 is linked to cardiovascular disorder.